51940-63-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 6-chloropyrimidine-4-carboxylate is used as an active pharmaceutical ingredient for the development of new drugs. Its chemical structure allows it to be a key component in the synthesis of various medications, contributing to the advancement of pharmaceutical treatments.
Used in Material Science:
In the field of material science, ethyl 6-chloropyrimidine-4-carboxylate is used as a research and development candidate. Its unique properties make it a valuable compound for exploring new materials and their potential applications in various industries.
Used in Chemical Laboratories:
Ethyl 6-chloropyrimidine-4-carboxylate is used as a synthetic intermediate in chemical laboratories, where it serves as a building block for the synthesis of more complex molecules. This role is crucial for the creation of new chemical entities and the study of their properties and potential uses.
As a Specialty Chemical:
Being a specialty chemical, ethyl 6-chloropyrimidine-4-carboxylate is often made-to-order for specific research or manufacturing processes. This tailored approach ensures that the compound meets the unique requirements of various projects, further expanding its utility and applications.

Upstream product

• 64-17-5 ethanol 
• 6299-87-2 6-hydroxypyrimidine-4-carboxylic acid 
• 762-21-0 acetylenedicarboxylic acid diethyl ester 
• 263270-52-6 6-chloropyrimidine-4-carbonyl chloride 

Downstream Products

• 1208980-88-4 ethyl 6-(phenylamino)pyrimidine-4-carboxylate 
• 1159009-10-5 6-[4-(2-oxo-2,3-dihydro-imidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid-[2-(2-fluoro-phenyl)-ethyl]-amide 
• 1426320-11-7 6-[3-chloro-4-(methoxymethyl)phenyl]pyrimidine-4-carboxylic acid 
• 1025351-41-0 (6-chloropyrimidin-4-yl)methanol 
• 1159007-39-2 1-{1-[6-(3-phenyl-pyrrolidin-1-carbonyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydroimidazo[4,5-b]pyridin-2-one 
• 1159007-33-6 6-[4-(2-oxo-2,3-dihydro-imidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid (2-m-tolylethyl)-amide 
• 1159007-53-0 6-[4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid-phenylamide 
• 1159006-95-7 7-methoxy-3-{1-[6-(3-phenyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-carbonyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists

The important roles of the CXCL12/CXCR4 axis in numerous pathogenic pathways involving HIV infection and cancer metastasis make the CXCR4 receptor an attractive target for the development of therapeutic agents. Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed. Compound 3 from this new scaffold demonstrates excellent binding affinity with CXCR4 receptor (IC50 = 54 nM) and inhibits CXCL12 induced cytosolic calcium increase (IC50 = 2.3 nM). Furthermore, compound 3 possesses good physicochemical properties (MW 353, clogP 2.0, PSA 48, pKa 6.7) and exhibits minimal hERG and CYP isozyme (e.g. 3A4, 2D6) inhibition. Collectively, these results strongly support further optimization of this novel scaffold to develop better CXCR4 antagonists.

METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS

Certain adjunctive therapies comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent for treating HIV-related disorders are provided herein. These disorders include AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis. Also provided are pharmaceutical compositions comprising a kynurenine-3- monooxygenase inhibitor and an antiviral agent.

SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and diso

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Compounds of formula (I): wherein R1, L2, R2, L3, R3, L4 and R4 are as defined herein, upregulate endogenous utrophin in predictive screens, and thus, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.

COMPOUNDS USEFUL AS RAF KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.